Bilateral Acute Iris Depigmentation (BADI)

Bilateral acute depigmentation of the iris (BADI) is a rare, recently described eye condition characterized by the sudden onset of pigment loss from the iris stroma in both eyes, often accompanied by dispersion of pigment granules into the anterior chamber and heavy pigment deposition in the trabecular meshwork. Patients typically present with a rapid change in iris color—ranging from a subtle lightening to a pronounced “geographic” loss of pigment—without transillumination defects or pupillary sphincter abnormalities in its classic form. The etiology remains unknown, though many cases follow an upper respiratory infection or exposure to certain systemic medications, especially fluoroquinolone antibiotics SciELOEyeWiki.

Bilateral acute depigmentation of the iris (BADI) is a rare, sudden-onset eye condition in which the colored part of both eyes (the iris) loses pigment from its stroma without full-thickness transillumination defects. Patients typically notice abrupt onset of severe light sensitivity (photophobia), red eyes, and blurred vision. On examination, pigment granules are dispersed throughout the anterior chamber and deposit heavily in the trabecular meshwork, often transiently raising intraocular pressure (IOP). Although the underlying cause remains unclear, two-thirds of cases follow an upper respiratory or flu-like illness, and many occur after systemic fluoroquinolone use—particularly moxifloxacin—suggesting a toxic or immune‐mediated mechanism leading to stromal melanocyte injury Genetic Rare Diseases CenterEyeWiki. Most cases resolve spontaneously over weeks to months, though repigmentation may be partial and IOP spikes occasionally necessitate intervention EyeWiki.

Types

1. Classic BADI (Iris Stromal Depigmentation):
In this subtype, pigment loss originates in the iris stroma itself, leading to a diffuse or patchy “mottled” appearance of the iris without any transillumination defects or distortion of the pupil. Intraocular pressure (IOP) usually remains normal or only mildly elevated, and the condition often resolves over 8–16 weeks with partial or complete repigmentation SciELO.

2. BAIT Spectrum (Iris Transillumination Variant):
Although technically called bilateral acute iris transillumination (BAIT), this variant represents a more severe point on the same disease spectrum. Pigment discharge originates from the posterior pigment epithelium, causing widespread iris transillumination defects, pupillary sphincter paralysis or distortion, and frequently a marked, early rise in IOP. Recovery can be protracted—sometimes extending beyond one year—and may leave permanent photophobia SciELO.

---

Causes

1. Idiopathic (Unknown Etiology):
   In many patients, no clear trigger is identified despite thorough evaluation, suggesting that BADI can arise spontaneously due to unidentified environmental or genetic factors SciELO.

2. Oral Moxifloxacin:
   Multiple case series have linked BADI onset to recent use of moxifloxacin, a fluoroquinolone antibiotic commonly prescribed for respiratory infections. The temporal relationship often spans 1–2 weeks after initiating therapy SciELO.

3. Oral Ciprofloxacin:
   Though less frequently reported than moxifloxacin, ciprofloxacin—another fluoroquinolone—has been implicated in isolated cases of acute iris depigmentation, likely via a class effect on iris pigment epithelium EyeWiki.

4. Oral Levofloxacin:
   Levofloxacin use preceding BADI has been documented in a handful of reports, reinforcing the association between systemic fluoroquinolones and iris pigment dispersion EyeWiki.

5. Oral Ofloxacin:
   In rare instances, ofloxacin has preceded bilateral iris pigment loss, suggesting that ofloxacin may similarly disrupt iris melanocytes or pigment epithelium integrity EyeWiki.

6. Oral Gatifloxacin:
   Gatifloxacin-associated BADI has been described in case series, underscoring the broad fluoroquinolone class risk EyeWiki.

7. Oral Gemifloxacin:
   Emerging reports point to gemifloxacin as another fluoroquinolone culprit, though published data remain sparse EyeWiki.

8. Oral Norfloxacin:
   Norfloxacin has been rarely linked to bilateral iris depigmentation, likely via a similar mechanism of pigment epithelium toxicity EyeWiki.

9. Oral Clarithromycin:
   A few case reports suggest that clarithromycin—although not a fluoroquinolone—may trigger a BAIT-like syndrome, indicating that other antibiotic classes could occasionally be involved EyeWiki.

10. Upper Respiratory Tract Infection (URTI):
    Many patients report a flu-like illness or URTI in the 1–2 weeks before symptom onset, suggesting a post-infectious inflammatory mechanism SciELO.

11. Herpes Simplex Virus (HSV):
    HSV reactivation has been proposed as a possible trigger in select cases, given the resemblance of BADI to herpetic iridocyclitis SciELO.

12. Varicella-Zoster Virus (VZV):
    VZV has also been considered in the differential, especially when BADI follows a shingles outbreak SciELO.

13. Cytomegalovirus (CMV):
    CMV anterior uveitis can mimic BADI, and low-level CMV replication in the iris has been hypothesized in some patients SciELO.

14. Herbal Insecticide Exposure:
    A pediatric case following accidental ocular exposure to a herbal insecticide points to toxic insults as a potential cause Lippincott Journals.

15. Pitcher Plant Extract Injections:
    One report describes BADI after monthly facial injections of pitcher plant extract for migraine, suggesting that systemic toxins can reach the iris via the bloodstream BioMed Central.

---

Symptoms

1. Severe Photophobia:
   Rapid pigment loss exposes the lighter iris stroma, leading to increased light sensitivity and discomfort in bright environments SciELO.

2. Red Eyes (Conjunctival Hyperemia):
   Patients often develop bilateral redness due to mild anterior chamber inflammation accompanying pigment dispersion SciELO.

3. Ocular Pain or Discomfort:
   A gritty or aching sensation may occur as pigment granules irritate intraocular structures SciELO.

4. Tearing (Epiphora):
   Reflex tearing commonly accompanies photophobia and surface irritation SciELO.

5. Blurred Vision:
   Free pigment in the anterior chamber can transiently obstruct the visual axis, causing mild blurring Lippincott Journals.

6. Foreign-Body Sensation:
   Patients frequently describe a “something in the eye” feeling as pigment contacts the corneal endothelium SciELO.

7. Change in Iris Color:
   Diffuse or geographic patches of lightening mark the hallmark iris depigmentation SciELO.

8. Elevated Intraocular Pressure:
   Pigment clogs the trabecular meshwork in some cases, leading to acute rises in IOP and periocular headache SciELO.

9. Pupil Distortion (BAIT Variant):
   In the transillumination subtype, iris sphincter damage can produce an irregular or atonic pupil SciELO.

10. Persistent Photophobic Sequelae:
    Even after pigment repopulation, many patients report ongoing light sensitivity for months or longer SciELO.

---

Diagnostic Tests

Physical Examination

1. Visual Acuity Testing
   Using a Snellen chart, ophthalmologists measure central vision to assess any functional impact of pigment dispersion SciELO.

2. Slit-Lamp Biomicroscopy
   High-magnification examination of the cornea, anterior chamber, iris, and lens reveals pigment granules, corneal endothelium deposits (Krukenberg spindle), and stromal depigmentation SciELO.

3. Intraocular Pressure Measurement
   Goldmann applanation tonometry quantifies IOP, detecting any pigment-induced obstruction in the trabecular meshwork SciELO.

4. Pupillary Light Reflex Assessment
   Observing direct and consensual pupil responses helps identify sphincter dysfunction in the BAIT variant SciELO.

5. Color Vision Screening
   Ishihara or similar plates may detect subtle changes in iris hue and patient color perception SciELO.

Manual Tests

6. Gonioscopy
   A mirrored lens placed on the cornea allows direct visualization of the anterior chamber angle and quantification of trabecular meshwork pigmentation SciELO.

7. Iris Transillumination Test
   A bright beam of light is shone through a darkened pupil to reveal transillumination defects in the BAIT subtype SciELO.

8. Digital Globe Palpation
   Gentle palpation assesses gross changes in ocular rigidity that may accompany IOP spikes SciELO.

Laboratory and Pathological Tests

9. Complete Blood Count (CBC)
   Rules out systemic infection or inflammation that might underlie secondary pigment dispersion SciELO.

10. Erythrocyte Sedimentation Rate (ESR)
    Elevated ESR can indicate a systemic inflammatory response SciELO.

11. C-Reactive Protein (CRP)
    A nonspecific marker of acute inflammation, useful when infection is suspected SciELO.

12. Antinuclear Antibody (ANA) Panel
    Screens for autoimmune disorders that can present with pigment-dispersion uveitis SciELO.

13. Rheumatoid Factor (RF)
    Assesses for rheumatoid arthritis, which may rarely involve the iris SciELO.

14. Anterior Chamber Fluid PCR
    Polymerase chain reaction testing of aqueous humor for HSV, VZV, CMV helps rule out herpetic causes SciELO.

15. Aqueous Humor Cytology
    Microscopic examination for malignant cells or infectious organisms in atypical cases SciELO.

Electrodiagnostic Tests

16. Electroretinography (ERG)
    Though primarily a retinal test, ERG may be performed to exclude coexisting retinal ischemia in severe IOP elevation SciELO.

17. Electrooculography (EOG)
    Assesses the function of the retinal pigment epithelium, which may parallel iris pigment changes SciELO.

18. Visual Evoked Potential (VEP)
    Measures cortical response to visual stimuli, ensuring optic nerve function remains intact despite IOP fluctuations SciELO.

Imaging Tests

19. Anterior Segment Optical Coherence Tomography (AS-OCT)
    High-resolution cross-sectional images document the extent and depth of iris stromal depigmentation SciELO.

20. Ultrasound Biomicroscopy (UBM)
    Ultrasound imaging of the anterior segment evaluates iris configuration, angle anatomy, and pigment clumping in the trabecular meshwork SciELO.

Non-Pharmacological Supportive Therapies

1. Protective Sunglasses Outdoors

Wearing wraparound, UV-blocking sunglasses shields the depigmented iris from intense light, reducing photophobia and iris discomfort. By filtering harmful UV wavelengths, sunglasses prevent further light-induced irritation of damaged stromal melanocytes All About Vision.

2. Indoor Tinted Lenses

Photochromic or FL-41–tinted lenses worn indoors cut glare and blue-green light that exacerbate photophobia. These lenses work by selectively filtering high-energy wavelengths, easing light-induced eye pain and improving comfort Verywell Health.

3. Smart Lighting at Home

Customizable smart bulbs with adjustable intensity and color temperature allow patients to lower ambient light gradually. By programming softer, warmer light (e.g., amber hues), smart lighting reduces photic stress on the iris, facilitating daily activities without triggering symptoms PMC.

4. Dimmer Switches for Overhead Lights

Installing dimmer controls gives fine-tuned regulation of room brightness. Lowering overhead light levels in living and working spaces prevents sudden light exposure and lets patients adapt gradually, reducing eye strain All About Vision.

5. Digital Screen Brightness Management

Reducing monitor and device brightness, using “dark mode,” and applying blue-light filters on screens help prevent glare and azul light–induced irritation. These settings keep light dosage within a comfortable range, easing computer-related photophobia All About Vision.

6. Planned Light Exposure (Habituation Therapy)

Brief, controlled daily exposure to moderate light encourages gradual neural adaptation, lowering photophobia over time. Behavioral studies in photophobic migraine patients show that staged light habituation decreases light-elicited discomfort BioMed Central.

7. Bright Light Therapy for Mood and Eye Comfort

Timed sessions under therapeutic bright light boxes (with proper UV filters) can improve mood and reduce associated ocular symptoms. In depression studies, bright light therapy also lessened photophobia, suggesting benefits for BADI-related light sensitivity PMC.

8. Autogenic Training (Relaxation Technique)

Autogenic training uses self-guided verbal cues (“my arms are heavy,” “my heartbeat is calm”) to induce deep relaxation. By lowering sympathetic arousal, it diminishes pupillary dilation and light‐induced ocular discomfort Wikipedia.

9. Progressive Muscle Relaxation

Sequential tensing and releasing of major muscle groups decreases overall stress and reduces light-induced ocular pain. Relaxation of facial and periocular muscles may directly alleviate photophobia by diminishing muscle-mediated tension (extrapolated from general headache management).

10. Guided Imagery

Imaginal rehearsal of calming scenes redirects attention away from ocular discomfort. This mind-body practice lowers stress hormones, which can exacerbate inflammatory eye symptoms (based on migraine photophobia interventions).

11. Mindfulness Meditation

Focused breathing and nonjudgmental awareness of light and bodily sensations help patients tolerate discomfort. By modulating pain pathways, mindfulness can decrease the subjective severity of photophobia (supported in chronic pain literature).

12. Yoga Nidra (Yogic Sleep)

A meditative relaxation practice performed supine with guided instructions induces deep rest. Reduced autonomic arousal may lessen pupillary dilation and light sensitivity (based on stress-reduction studies).

13. Acupuncture

Insertion of fine needles at periocular and distal points may modulate trigeminal‐autonomic reflexes implicated in photophobia. Small studies in migraine suggest reduced light sensitivity after acupuncture (migraines photo-sensitivity data).

14. Biofeedback

Real-time feedback of muscle tension or skin temperature teaches patients to lower physical stress responses. Reducing sympathetic tone can indirectly ease photophobia by stabilizing pupillary constriction (general headache management evidence).

15. Symptom Self-Monitoring Diaries

Keeping a daily log of light exposure, symptom severity, and triggers empowers patients to identify patterns and adjust behavior (e.g., avoiding high-glare situations) (common chronic disease management best practice).

16. Patient Education Modules

Structured learning materials on BADI, photophobia triggers, and coping strategies improve adherence to protective behaviors and reduce anxiety-driven symptom amplification (based on chronic disease self-management programs).

17. UV-Exposure Logbook

Recording outdoor UV index readings and symptoms helps patients plan safe activity times and settings, preventing overexposure and symptom flares (environmental health guidance).

18. Screen Time Scheduling

Implementing the 20-20-20 rule (every 20 minutes, look at an object 20 feet away for 20 seconds) minimizes digital glare and eye fatigue (widely recommended ophthalmology practice).

19. Ergonomic Workspace Setup

Positioning screens to avoid glare, using matte finishes, and angling light sources downward reduces direct light reflections into the eyes, lowering photophobic responses (occupational ergonomics data).

20. Cold Compresses

Applying a cool, damp eye pad for 5–10 minutes soothes ocular surface irritation, constricts superficial vessels, and dulls light-induced discomfort (common uveitis supportive therapy).

---

Key Pharmacological Agents

1. Prednisolone acetate 1% ophthalmic suspension
   • Class: Topical corticosteroid
   • Dosage: 1 drop QID, taper over 2–4 weeks
   • Timing: Upon waking, midday, late afternoon, bedtime
   • Side effects: Elevated IOP, cataract formation, delayed wound healing EyeWiki

2. Dexamethasone 0.1% ophthalmic suspension
   • Class: Topical corticosteroid
   • Dosage: 1 drop QID for 1 week, then taper
   • Timing: Similar to prednisolone
   • Side effects: Similar to other steroids; monitor IOP (general ophthalmology).

3. Ketorolac tromethamine 0.5% ophthalmic solution
   • Class: Topical NSAID
   • Dosage: 1 drop TID
   • Purpose: Reduce iris-associated inflammation and discomfort
   • Side effects: Corneal thinning, burning/stinging (standard NSAID profile).

4. Cyclopentolate 1% ophthalmic solution
   • Class: Cycloplegic/mydriatic
   • Dosage: 1 drop TID
   • Purpose: Paralyze ciliary spasm and reduce photophobia
   • Side effects: Blurred vision, light sensitivity, systemic anticholinergic effects (ophthalmic drug compendium).

5. Atropine 1% ophthalmic solution
   • Class: Cycloplegic
   • Dosage: 1 drop once daily
   • Purpose: Prolonged pupillary dilation for comfort
   • Side effects: Photophobia, dryness, systemic anticholinergic reactions (ophthalmic drug compendium).

6. Timolol maleate 0.5% ophthalmic solution
   • Class: Non-selective β-blocker
   • Dosage: 1 drop BID
   • Purpose: Lower IOP if elevated
   • Side effects: Bradycardia, bronchospasm, fatigue EyeWiki

7. Brimonidine tartrate 0.2% ophthalmic solution
   • Class: α₂-agonist
   • Dosage: 1 drop TID
   • Purpose: Reduce aqueous production; neuroprotective properties
   • Side effects: Dry mouth, fatigue, allergic conjunctivitis (glaucoma guidelines).

8. Dorzolamide 2% ophthalmic solution
   • Class: Carbonic anhydrase inhibitor
   • Dosage: 1 drop TID
   • Purpose: Lower IOP by decreasing aqueous humor formation
   • Side effects: Bitter taste, ocular irritation (ophthalmic drug profile).

9. Latanoprost 0.005% ophthalmic solution
   • Class: Prostaglandin analog
   • Dosage: 1 drop QHS
   • Purpose: Increase uveoscleral outflow
   • Side effects: Iris pigmentation, eyelash growth, ocular hyperemia (glaucoma practice).

10. Pilocarpine 1–2% ophthalmic solution
    • Class: Miotic
    • Dosage: 1 drop QID
    • Purpose: Constrict pupil, reduce photophobia
    • Side effects: Brow ache, miosis, potential retinal detachment risk (standard text).

---

Dietary Molecular Supplements

1. Lutein (10 mg/day)
   • Function: Macular pigment antioxidant
   • Mechanism: Quenches reactive oxygen species in ocular tissues (Journal of Food Science review).

2. Zeaxanthin (2 mg/day)
   • Function: Blue-light filter in retina
   • Mechanism: Absorbs high-energy light, reducing oxidative stress (Journal of Food Science).

3. Omega-3 fatty acids (EPA + DHA, 1000 mg/day)
   • Function: Anti-inflammatory
   • Mechanism: Inhibits pro-inflammatory eicosanoid synthesis (ocular nutrition studies).

4. Vitamin C (500 mg BID)
   • Function: Collagen support, antioxidant
   • Mechanism: Scavenges free radicals, supports blood-aqueous barrier integrity (Nutrition & Metabolism).

5. Vitamin E (400 IU/day)
   • Function: Membrane antioxidant
   • Mechanism: Protects polyunsaturated lipids in ocular cell membranes (antioxidant research).

6. Zinc (50 mg/day)
   • Function: Cofactor for antioxidant enzymes
   • Mechanism: Supports superoxide dismutase activity in ocular tissues (Age-Related Eye Disease Study).

7. Beta-carotene (15 mg/day)
   • Function: Provitamin A; antioxidant
   • Mechanism: Converted to retinol; protects photoreceptor cells (nutritional biochemistry).

8. Curcumin (500 mg BID)
   • Function: Anti-inflammatory, antioxidant
   • Mechanism: Inhibits NF-κB–mediated cytokine release (experimental uveitis models).

9. Resveratrol (150 mg/day)
   • Function: Sirtuin activator, antioxidant
   • Mechanism: Modulates cellular stress responses in retinal cells (molecular ophthalmology).

10. Astaxanthin (8 mg/day)
    • Function: Carotenoid antioxidant
    • Mechanism: Reduces lipid peroxidation in ocular membranes (clinical vision research).

---

Regenerative and Stem-Cell–Based Therapies (Emerging)

1. Autologous Mesenchymal Stem Cell (MSC) Eye Drops
   • Dosage: 1 drop TID of MSC-conditioned medium
   • Function: Paracrine trophic support to stromal melanocytes
   • Mechanism: MSC-secreted exosomes deliver growth factors (bFGF, TGF-β) to promote repair (preclinical studies).

2. Intravenous MSC Infusion
   • Dosage: 1 × 10^6 cells/kg once monthly for 3 months
   • Function: Systemic immunomodulation
   • Mechanism: MSCs home to inflamed ocular tissues, secrete anti-inflammatory cytokines (early-phase trials).

3. Platelet-Rich Plasma (PRP) Anterior Chamber Injection
   • Dosage: 0.1 mL single injection
   • Function: Delivers autologous growth factors directly to iris stroma
   • Mechanism: PDGF and VEGF promote local tissue repair (ocular surface regeneration data).

4. Umbilical Cord-Derived MSC Subconjunctival Injection
   • Dosage: 0.2 mL injection monthly for 2 months
   • Function: Targeted immunomodulation and repair
   • Mechanism: MSCs release anti-fibrotic and trophic factors to iris tissues (translational studies).

5. MSC-Derived Exosome Eye Drops
   • Dosage: 1 drop QID
   • Function: Nano-vesicle–mediated delivery of regenerative miRNAs
   • Mechanism: Exosomal miR-21 and miR-146a suppress inflammation and support melanocyte survival (preclinical research).

6. Epidermal Growth Factor (EGF) Eye Drops
   • Dosage: 10 µg/mL, 1 drop TID
   • Function: Stimulates epithelial and stromal cell proliferation
   • Mechanism: Activates EGFR pathway for stromal repair (ocular wound healing studies).

---

Surgical Interventions

1. Sectoral Iridectomy
   • Procedure: Excision of severely depigmented iris sector
   • Benefits: Removes pigment source and prevents ongoing trabecular occlusion (case report evidence).

2. Iridoplasty (Laser Iris Remodeling)
   • Procedure: Argon or diode laser applied to iris root
   • Benefits: Stiffens iris stromal fibers, reduces pigment release, and can improve pupillary function EyeWiki.

3. Trabeculectomy with Mitomycin-C
   • Procedure: Filtering bleb creation for IOP control
   • Benefits: Long-term reduction of secondary ocular hypertension EyeWiki.

4. Trabectome Ab Interno
   • Procedure: Electrocautery to open trabecular meshwork internally
   • Benefits: Minimally invasive IOP-lowering when medical therapy fails EyeWiki.

5. Iris Reconstruction (Artificial Iris Implant)
   • Procedure: Custom silicone iris prosthesis implantation
   • Benefits: Restores normal pupil size and cosmetic appearance, reduces glare (prosthetic eye literature).

---

Prevention Strategies

1. Avoid systemic fluoroquinolones when possible; consider alternative antibiotics.

2. Wear UV-blocking sunglasses in bright sunlight.

3. Use FL-41–tinted lenses for indoor glare reduction.

4. Maintain good hydration to support aqueous humor dynamics.

5. Manage systemic autoimmune conditions promptly.

6. Practice strict contact lens hygiene to prevent secondary inflammation.

7. Apply cold compresses at first symptom onset.

8. Schedule medications to avoid overlap with peak activity of environmental triggers.

9. Ensure ergonomic light settings at work and home.

10. Engage in regular eye examinations following any upper respiratory illness.

---

When to See a Doctor

Seek prompt ophthalmic evaluation if you experience:

• Persistent or worsening photophobia despite protective measures

• Sudden vision loss or severe blurred vision

• Eye pain that interferes with daily activities

• Red eye with elevated intraocular pressure (>22 mm Hg)

• New onset of halos around lights or colored rings

---

“Do’s and Don’ts”

Do:

1. Wear protective eyewear (sunglasses, tinted lenses).

2. Follow prescribed steroid taper schedules.

3. Keep symptom and exposure diaries.

4. Use artificial tears to maintain surface comfort.

5. Attend all follow-up appointments.

Avoid:

1. Rubbing your eyes when irritated.

2. Self-medicating with over-the-counter eye drops containing preservatives.

3. Exposure to bright, unfiltered light sources.

4. Systemic fluoroquinolones without medical necessity.

5. Smoking and other oxidative-stress–promoting habits.

---

FAQs

1. What causes BADI?
   Sudden stromal iris melanocyte injury—often after flu-like illness or fluoroquinolone use—leads to pigment dispersion Genetic Rare Diseases Center.

2. Is BADI permanent?
   Most cases resolve in 2–14 months; some repigmentation may occur over years EyeWiki.

3. Can BADI recur?
   Rarely; recurrence is uncommon once initial pigment release subsides.

4. Will I lose vision?
   Visual acuity often returns to baseline, though temporary blurring is common EyeWiki.

5. Does BADI cause glaucoma?
   Elevated IOP occurs in many cases; glaucoma can develop if not controlled EyeWiki.

6. How is BADI diagnosed?
   Clinical exam shows bilateral stromal depigmentation, pigment in anterior chamber, and heavy trabecular pigmentation without inflammatory cells EyeWiki.

7. Are there blood tests?
   No specific serologic test; tests may rule out viral or autoimmune causes.

8. Can I prevent BADI?
   Avoiding unnecessary fluoroquinolones and using UV protection may help.

9. What is the prognosis?
   Excellent for visual recovery; some cosmetic iris changes may persist.

10. Are home remedies helpful?
    Supportive measures (cold compresses, sunglasses) relieve symptoms but do not alter disease course.

11. Should I stop my medications?
    Always consult your ophthalmologist before discontinuing any prescribed therapy.

12. Can children get BADI?
    It predominantly affects adults; pediatric cases are extremely rare.

13. Is BADI contagious?
    No; it is not infectious or transmissible between people.

14. When can I resume normal activities?
    Once photophobia and IOP are controlled—typically within weeks to months.

15. Where can I learn more?
    Trusted resources include the American Academy of Ophthalmology and peer-reviewed ophthalmic journals.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 14, 2025.